SE454403B - Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel - Google Patents
Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedelInfo
- Publication number
- SE454403B SE454403B SE8402938A SE8402938A SE454403B SE 454403 B SE454403 B SE 454403B SE 8402938 A SE8402938 A SE 8402938A SE 8402938 A SE8402938 A SE 8402938A SE 454403 B SE454403 B SE 454403B
- Authority
- SE
- Sweden
- Prior art keywords
- fibronectin
- protein
- collagen
- binding
- cell surface
- Prior art date
Links
- 102000016359 Fibronectins Human genes 0.000 title claims abstract description 33
- 108010067306 Fibronectins Proteins 0.000 title claims abstract description 33
- 102000008186 Collagen Human genes 0.000 title claims abstract description 18
- 108010035532 Collagen Proteins 0.000 title claims abstract description 18
- 229920001436 collagen Polymers 0.000 title claims abstract description 18
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 18
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims abstract 3
- -1 FIBRINOGENE Proteins 0.000 title 1
- 102000018697 Membrane Proteins Human genes 0.000 claims abstract description 26
- 108010052285 Membrane Proteins Proteins 0.000 claims abstract description 26
- 230000001580 bacterial effect Effects 0.000 claims abstract description 24
- 102000007547 Laminin Human genes 0.000 claims abstract description 18
- 108010085895 Laminin Proteins 0.000 claims abstract description 18
- 102000008946 Fibrinogen Human genes 0.000 claims abstract description 15
- 108010049003 Fibrinogen Proteins 0.000 claims abstract description 15
- 229940012952 fibrinogen Drugs 0.000 claims abstract description 15
- 238000005406 washing Methods 0.000 claims abstract description 6
- 238000000746 purification Methods 0.000 claims abstract description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 21
- 238000002649 immunization Methods 0.000 claims description 11
- 230000003053 immunization Effects 0.000 claims description 11
- 238000012258 culturing Methods 0.000 claims description 7
- 238000001042 affinity chromatography Methods 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- 230000001717 pathogenic effect Effects 0.000 claims description 4
- 238000010828 elution Methods 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 230000000699 topical effect Effects 0.000 claims description 3
- 241000191967 Staphylococcus aureus Species 0.000 claims description 2
- 238000004587 chromatography analysis Methods 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 abstract description 14
- 208000004396 mastitis Diseases 0.000 abstract description 8
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 241000282849 Ruminantia Species 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 206010052428 Wound Diseases 0.000 description 30
- 208000027418 Wounds and injury Diseases 0.000 description 28
- 208000015181 infectious disease Diseases 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 8
- 241000295644 Staphylococcaceae Species 0.000 description 7
- 210000000481 breast Anatomy 0.000 description 7
- 210000004080 milk Anatomy 0.000 description 6
- 239000008267 milk Substances 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 235000013336 milk Nutrition 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 4
- 102000009027 Albumins Human genes 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 4
- 235000001014 amino acid Nutrition 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000002808 connective tissue Anatomy 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000002255 vaccination Methods 0.000 description 4
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
- 210000003709 heart valve Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- SPIWINZXMDJUPE-UHFFFAOYSA-N 4-methoxy-3-(3-methylbut-2-enyl)-1h-quinolin-2-one Chemical compound C1=CC=C2C(OC)=C(CC=C(C)C)C(O)=NC2=C1 SPIWINZXMDJUPE-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 101000815632 Streptococcus suis (strain 05ZYH33) Rqc2 homolog RqcH Proteins 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000002919 epithelial cell Anatomy 0.000 description 2
- 102000036072 fibronectin binding proteins Human genes 0.000 description 2
- 244000309465 heifer Species 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000002445 nipple Anatomy 0.000 description 2
- 239000002504 physiological saline solution Substances 0.000 description 2
- 239000012460 protein solution Substances 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 229910000162 sodium phosphate Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000003685 thermal hair damage Effects 0.000 description 2
- 230000000451 tissue damage Effects 0.000 description 2
- 231100000827 tissue damage Toxicity 0.000 description 2
- 230000008733 trauma Effects 0.000 description 2
- 230000000472 traumatic effect Effects 0.000 description 2
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 2
- 210000001635 urinary tract Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 108010062271 Acute-Phase Proteins Proteins 0.000 description 1
- 102000011767 Acute-Phase Proteins Human genes 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 208000031462 Bovine Mastitis Diseases 0.000 description 1
- 108010074051 C-Reactive Protein Proteins 0.000 description 1
- 102100032752 C-reactive protein Human genes 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000002356 Nectin Human genes 0.000 description 1
- 108060005251 Nectin Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 229920005654 Sephadex Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- TTWYZDPBDWHJOR-IDIVVRGQSA-L adenosine triphosphate disodium Chemical compound [Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O TTWYZDPBDWHJOR-IDIVVRGQSA-L 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000001420 bacteriolytic effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012267 brine Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000003196 chaotropic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- ZNNZYHKDIALBAK-UHFFFAOYSA-M potassium thiocyanate Chemical compound [K+].[S-]C#N ZNNZYHKDIALBAK-UHFFFAOYSA-M 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- VGTPCRGMBIAPIM-UHFFFAOYSA-M sodium thiocyanate Chemical compound [Na+].[S-]C#N VGTPCRGMBIAPIM-UHFFFAOYSA-M 0.000 description 1
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000012899 standard injection Substances 0.000 description 1
- 238000011477 surgical intervention Methods 0.000 description 1
- 238000007669 thermal treatment Methods 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 108010050327 trypticase-soy broth Proteins 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
- C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Pregnancy & Childbirth (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Gynecology & Obstetrics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Materials For Medical Uses (AREA)
Priority Applications (14)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8402938A SE454403B (sv) | 1984-05-30 | 1984-05-30 | Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel |
| IE133785A IE59203B1 (en) | 1984-05-30 | 1985-05-29 | The use of a cell surface protein obtained from staph.aureus |
| NZ212244A NZ212244A (en) | 1984-05-30 | 1985-05-29 | Preparation of cell surface protein of fibronectin binding properties useful as topical anti-infectant and vaccine |
| CA000482662A CA1340401C (en) | 1984-05-30 | 1985-05-29 | Cell surface protein, process for its preparation, and the use of a cell surface protein thus obtained |
| ES543635A ES8900019A1 (es) | 1984-05-30 | 1985-05-29 | Un procedimiento para fabricar una proteina de la superficiede las celulas |
| DE8585850190T DE3577579D1 (de) | 1984-05-30 | 1985-05-30 | Verwendung eines zelloberflaechenprotein gewonnen aus staph. aureus. |
| AU44331/85A AU600886B2 (en) | 1984-05-30 | 1985-05-30 | Fibronectin-binding protein |
| PCT/SE1985/000227 WO1985005553A1 (en) | 1984-05-30 | 1985-05-30 | Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and profylactic treatment |
| AT85850190T ATE52543T1 (de) | 1984-05-30 | 1985-05-30 | Verwendung eines zelloberflaechenprotein gewonnen aus staph. aureus. |
| EP85850190A EP0163623B1 (de) | 1984-05-30 | 1985-05-30 | Verwendung eines Zelloberflächenprotein gewonnen aus Staph. aureus |
| JP60502661A JPH0747541B2 (ja) | 1984-05-30 | 1985-05-30 | 細胞表面蛋白質とその製法及びその使用法 |
| FI860417A FI84431C (fi) | 1984-05-30 | 1986-01-29 | Foerfarande foer framstaellning av ett fibronektinbindande cellyteprotein. |
| NO86860321A NO164992C (no) | 1984-05-30 | 1986-01-29 | Fremgangsmaate for fremstilling av bakerielt overflateprotein med fibronektinbindende egenskaper. |
| US07/801,593 US5189015A (en) | 1984-05-30 | 1991-12-05 | Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE8402938A SE454403B (sv) | 1984-05-30 | 1984-05-30 | Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| SE8402938D0 SE8402938D0 (sv) | 1984-05-30 |
| SE8402938L SE8402938L (sv) | 1985-12-01 |
| SE454403B true SE454403B (sv) | 1988-05-02 |
Family
ID=20356083
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE8402938A SE454403B (sv) | 1984-05-30 | 1984-05-30 | Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0163623B1 (de) |
| JP (1) | JPH0747541B2 (de) |
| AT (1) | ATE52543T1 (de) |
| AU (1) | AU600886B2 (de) |
| CA (1) | CA1340401C (de) |
| DE (1) | DE3577579D1 (de) |
| ES (1) | ES8900019A1 (de) |
| FI (1) | FI84431C (de) |
| IE (1) | IE59203B1 (de) |
| NO (1) | NO164992C (de) |
| NZ (1) | NZ212244A (de) |
| SE (1) | SE454403B (de) |
| WO (1) | WO1985005553A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8702272L (sv) * | 1987-06-01 | 1988-12-02 | Alfa Laval Agri Int | Fibronektinbindande protein samt dess framstaellning |
| SE8801723D0 (sv) * | 1988-05-06 | 1988-05-06 | Staffan Normark | Fibronectin binding protein as well as its preparation |
| SE8801894D0 (sv) * | 1988-05-20 | 1988-05-20 | Alfa Laval Agri Int | Fibronektinbindande protein |
| SE8901687D0 (sv) * | 1989-05-11 | 1989-05-11 | Alfa Laval Agri Int | Fibronectin binding protein as well as its preparation |
| US5440014A (en) * | 1990-08-10 | 1995-08-08 | H+E,Uml/Oo/ K; Magnus | Fibronectin binding peptide |
| SE9003374D0 (sv) * | 1990-10-22 | 1990-10-22 | Alfa Laval Agri Int | A collagen binding protein as well as its preparation |
| US5980908A (en) * | 1991-12-05 | 1999-11-09 | Alfa Laval Ab | Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment |
| EP0621875B1 (de) * | 1992-09-21 | 2002-03-27 | Alfa-Laval Agri International Ab | Fibrinogen-bildungsprotein |
| JPH0840932A (ja) | 1994-07-29 | 1996-02-13 | Kitasato Inst:The | スタフイロコッカス属菌感染症の予防ワクチン及び治療用抗体並びにそれの製造法 |
| GB9415902D0 (en) * | 1994-08-05 | 1994-09-28 | Smithkline Beecham Plc | Method of treatment |
| US6685943B1 (en) | 1997-01-21 | 2004-02-03 | The Texas A&M University System | Fibronectin binding protein compositions and methods of use |
| ES2322409T3 (es) * | 1998-08-31 | 2009-06-19 | Inhibitex, Inc. | Vacunas multicomponentes contra staphylococcus aureus. |
| US6703025B1 (en) | 1998-08-31 | 2004-03-09 | Inhibitex, Inc. | Multicomponent vaccines |
| US6692739B1 (en) * | 1998-08-31 | 2004-02-17 | Inhibitex, Inc. | Staphylococcal immunotherapeutics via donor selection and donor stimulation |
| US6908994B1 (en) | 1999-05-10 | 2005-06-21 | The Texas A&M University System | Collagen-binding proteins from enterococcal bacteria |
| CA2517439C (en) | 2003-03-07 | 2013-07-23 | Wyeth Holdings Corporation | Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| EA014352B1 (ru) | 2005-08-10 | 2010-10-29 | Арне Форсгрен Аб | Взаимодействие moraxella catarrhalis с эпителиальными клетками, внеклеточными матриксными белками и системой комплемента |
| SA110310528B1 (ar) | 2009-06-22 | 2014-07-02 | Wyeth Llc | التركيبات المولدة للمناعة لأنتيجينات ستافيلوكوكس أوريس |
| GB0913680D0 (en) | 2009-08-05 | 2009-09-16 | Glaxosmithkline Biolog Sa | Immunogenic composition |
| TW201302779A (zh) | 2011-04-13 | 2013-01-16 | Glaxosmithkline Biolog Sa | 融合蛋白質及組合疫苗 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU561067B2 (en) * | 1982-03-22 | 1987-04-30 | Biocarb Ab | Anti-bacterial composition containing an oligosaccharide |
-
1984
- 1984-05-30 SE SE8402938A patent/SE454403B/sv not_active IP Right Cessation
-
1985
- 1985-05-29 ES ES543635A patent/ES8900019A1/es not_active Expired
- 1985-05-29 NZ NZ212244A patent/NZ212244A/xx unknown
- 1985-05-29 IE IE133785A patent/IE59203B1/en not_active IP Right Cessation
- 1985-05-29 CA CA000482662A patent/CA1340401C/en not_active Expired - Lifetime
- 1985-05-30 JP JP60502661A patent/JPH0747541B2/ja not_active Expired - Fee Related
- 1985-05-30 AU AU44331/85A patent/AU600886B2/en not_active Expired
- 1985-05-30 EP EP85850190A patent/EP0163623B1/de not_active Expired - Lifetime
- 1985-05-30 DE DE8585850190T patent/DE3577579D1/de not_active Expired - Lifetime
- 1985-05-30 AT AT85850190T patent/ATE52543T1/de not_active IP Right Cessation
- 1985-05-30 WO PCT/SE1985/000227 patent/WO1985005553A1/en not_active Ceased
-
1986
- 1986-01-29 NO NO86860321A patent/NO164992C/no unknown
- 1986-01-29 FI FI860417A patent/FI84431C/fi not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE8402938L (sv) | 1985-12-01 |
| EP0163623A3 (en) | 1987-02-25 |
| JPS61502334A (ja) | 1986-10-16 |
| IE851337L (en) | 1985-11-30 |
| FI860417L (fi) | 1986-01-29 |
| EP0163623B1 (de) | 1990-05-09 |
| FI84431B (fi) | 1991-08-30 |
| NO860321L (no) | 1986-01-29 |
| FI84431C (fi) | 1991-12-10 |
| JPH0747541B2 (ja) | 1995-05-24 |
| DE3577579D1 (de) | 1990-06-13 |
| FI860417A0 (fi) | 1986-01-29 |
| EP0163623A2 (de) | 1985-12-04 |
| NO164992B (no) | 1990-08-27 |
| ES543635A0 (es) | 1988-11-01 |
| IE59203B1 (en) | 1994-01-26 |
| ES8900019A1 (es) | 1988-11-01 |
| CA1340401C (en) | 1999-02-23 |
| SE8402938D0 (sv) | 1984-05-30 |
| ATE52543T1 (de) | 1990-05-15 |
| AU600886B2 (en) | 1990-08-30 |
| WO1985005553A1 (en) | 1985-12-19 |
| NO164992C (no) | 1990-12-05 |
| NZ212244A (en) | 1989-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5189015A (en) | Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability | |
| SE454403B (sv) | Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel | |
| US5980908A (en) | Bacterial cell surface protein with fibronectin, fibrinogen, collagen and laminin binding ability, process for the manufacture of the protein and prophylactic treatment | |
| JP3430853B2 (ja) | 胃炎、胃潰瘍および十二指腸潰瘍の予防剤並びに治療剤 | |
| AU4433185A (en) | Fibronectin-binding protein | |
| US20150210757A1 (en) | Polypeptides and immunizing compositions containing gram positive polypeptides and methods of use | |
| US6391315B1 (en) | Vaccine for inhibiting and preventing induced staphylococcus infection, isolated antigens used therein, and isolated antibodies induced thereby | |
| Loganathan et al. | Lysozyme, protease, alkaline phosphatase and esterase activity of epidermal skin mucus of freshwater snake head fish Channa striatus | |
| SE446688B (sv) | Medel for avlegsnande av mikroorganismer fran vevnader, vilket bestar av ett protein som kan bindas till mikroorganismerna | |
| Stewart | Streptococcus and enterococcus | |
| CA2257826A1 (en) | Helicobacter pylori adhesin binding group antigen | |
| Cole et al. | Stimulation of mouse lymphocytes by a mitogen derived from Mycoplasma arthritidis. II. Cellular requirements for T cell transformation mediated by a soluble Mycoplasma mitogen. | |
| US5703040A (en) | Broad spectrum antibiotic peptide | |
| EP1926811B1 (de) | Herstellung und reinigung von protein a ohne die verwendung von tierischen komponenten | |
| Schauer et al. | Sialidase activity in the sera of patients and rabbits with clostridial myonecrosis | |
| US6884412B1 (en) | Dectection of and methods and composition for prevention and/or treatment of papillomatous digital dermatitis | |
| US20020107174A1 (en) | Composition comprising endotoxin neutralizing protein and derivatives and uses thereof | |
| Kessel et al. | Endotoxin cytotoxicity: role of cell-associated antibody. | |
| AU714222B2 (en) | Helicobacter pylori antigen | |
| Hibbitt et al. | The antimicrobial activity of cationic proteins isolated from the cells in bulk milk samples | |
| Whelihan | The isolation and characterization of antibacterial factors from bovine seminal plasma and pancreas: a thesis presented in partial fulfilment of the requirements for the degree of Master of Science in Microbiology at Massey University | |
| JPH07274993A (ja) | 抗原の調製方法及び抗体 | |
| Bharadwaj et al. | Umbilical cord blood serum extract as an antimicrobial biomaterial on streptococcus mutans and Lactobacillus acidophilus | |
| NO861580L (no) | Fremgangsmaate for fremstilling av celleadhesjonsinhibitorer. | |
| Oliver | An attempt to alter the rate of involution and the natural resistance to infection in the bovine mammary gland by infusion of endotoxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| NAL | Patent in force |
Ref document number: 8402938-8 Format of ref document f/p: F |
|
| NUG | Patent has lapsed |